Hematology

CD98 molecule could be a potential therapeutic target in AML.

The companies plan to collaborate on clinical trials of a novel combination therapy for multiple myeloma.

Rituximab is a cancer medication that can be used in combination with methotrexate to treat symptoms of adult rheumatoid arthritis.

The FDA has accepted the biologics license application from Genentech for a subcutaneous formulation of rituximab for multiple blood cancer indications.

Top news of the week in oncology and cancer drug development.

Developed countries may be able to assist developing countries in ensuring their drugs are safe.

Xgeva targets the RANK ligand pathways to prevent the creation, function, and survival of osteoclasts.

Amgen announces top-line results from trial evaluating Xgeva in multiple myeloma.

Top news of the week in oncology and cancer drug development.

Researchers found a low-cost approach to examine individual cancer cells, which could lead to a breakthrough in treatments.

Top news of the week in oncology and cancer drug development.

Celgene and Agios will collaborate with a technology company to improve diagnostics for patients with acute myeloid leukemia.

Top news of the day from across the health care landscape.

Patients with memory dysfunctions or depression may be less likely maintain adherence to oral oncoltyics.

Top news of the week from The American Journal of Pharmacy Benefits.

Top news of the week in oncology, and cancer drug development.

Top news of the week in oncology, and cancer drug development.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

Top news of the week in cancer research.

Whether or not cancer cells remain in a cancer patient while undergoing treatment may effect multiple myeloma survival.

DHODH inhibitor caused a reduction in leukemic stem cells and long-term remission in mice.

Pevonedistat shows potential to stop melanoma and other types of cancer.

Top news of the week in oncology, and cancer drug development.

Top news of the day from across the healthcare landscape.

Top news of the week in oncology, and cancer drug development.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

The median charge of treatment for a 6-day hospital stay totals $37,000 in young cancer patients in need of stem cell transplants.

The FDA has expanded the use of Amgen's blinatumomab (Blincyto) to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients.